Last edition
News about "Infex Therapeutics "
Junshi Biosciences expands toripalimab’s treatment footprint in China with regulatory approval for a new urothelial carcinoma indication, strengthening immunotherapy options for patients with advanced bladder cancer.
Infex Therapeutics | 25/05/2026 | By News Bureau
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Infex Therapeutics | 25/05/2026 | By News Bureau
Venus Remedies Bags Exclusive Licensing Rights for MET-X from Infex Therapeutics
This strategic collaboration grants Venus Remedies the rights to spearhead clinical development, regulatory approvals, and commercialization of MET-X in India, focusing on its integration with meropenem to tackle infections resistant to conventional treatments.
Infex Therapeutics | 28/02/2025 | By Aishwarya | 582
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy